Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years.

Autor: Berning P; Department of Hematology and Oncology, University Hospital Muenster, Muenster, Germany., Fekom M; European Society for Blood and Marrow Transplantation, Paris, France., Ngoya M; European Society for Blood and Marrow Transplantation, Paris, France., Goldstone AH; HCA Healthcare, Macmillan Cancer Centre, London, United Kingdom., Dreger P; Department of Medicine V, University of Heidelberg, Heidelberg, Germany., Montoto S; St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Finel H; European Society for Blood and Marrow Transplantation, Paris, France., Shumilov E; Department of Hematology and Oncology, University Hospital Muenster, Muenster, Germany., Chevallier P; Department of Hematology, CHU Nantes, Nantes, France., Blaise D; Transplantation and Cellular Immunotherapy Program, Department of Hematology, Instititut Paoli Calmettes, MSC Lab, Aix Marseille University, Marseille, France., Strüssmann T; Department of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany., Carpenter B; Department of Hematology, University College London Hospitals, London, United Kingdom., Forcade E; Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, F-33000, Bordeaux, France., Castilla-Llorente C; Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France., Trneny M; First Faculty of Medicine, Charles University, Praha, Czech Republic., Ghesquieres H; Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'Hématologie, Pierre Bénite, France., Capria S; Department of Translational and Precision Medicine, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy., Thieblemont C; Department of Hemato-Oncology, Hôpital Saint-Louis APHP, Paris, France., Blau IW; Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität Berlin, Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Berlin, Germany., Meijer E; Department of Hematology, Amsterdam University Medical Center, Free University, Amsterdam, the Netherlands., Broers AEC; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Huynh A; CHU - Institut Universitaire du Cancer Toulouse, Oncopole, I.U.C.T-O, Toulouse, France., Caillot D; Department of Hematology, CHU Dijon, Dijon, France., Rösler W; Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany., Nguyen Quoc S; Department of Hematology, AP-HP, Sorbonne Université, Pitié- Salpêtrière Hospital, Paris, France., Bittenbring J; Department of Hematology and Oncology, Saarland University Medical School, Homburg, Germany., Nagler A; Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel., Galimard JE; European Society for Blood and Marrow Transplantation, Paris, France., Glass B; Department of Hematology, Oncology, Tumor Immunology, and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany., Sureda A; Department of Hematology, Institut Català d'Oncologia Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Schmitz N; Department of Hematology and Oncology, University Hospital Muenster, Muenster, Germany. norbert.schmitz@ukmuenster.de.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2024 Jul 05; Vol. 14 (1), pp. 106. Date of Electronic Publication: 2024 Jul 05.
DOI: 10.1038/s41408-024-01085-9
Abstrakt: Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 cases in 2018. The recent decline in transplants corresponds to increased CAR-T treatments (1117 cases in 2021). Median age for auto-HSCT rose from 42 (1990-1994) to 58 years (2015-2021), with peripheral blood becoming the primary stem cell source post-1994. Allo-HSCT median age increased from 36 (1990-1994) to 54 (2015-2021) years, with mobilized blood as the primary source post-1998 and reduced intensity conditioning post-2000. Unrelated and mismatched allo-HSCT accounted for 50% and 19% of allo-HSCT in 2015-2021. Three-year overall survival (OS) after auto-HSCT improved from 56% (1990-1994) to 70% (2015-2021), p < 0.001, with a decrease in relapse incidence (RI) from 49% to 38%, while non-relapse mortality (NRM) remained unchanged (4%). After allo-HSCT, 3-year-OS increased from 33% (1990-1999) to 46% (2015-2021) (p < 0.001); 3-year RI remained at 39% and 1-year-NRM decreased to 19% (p < 0.001). Our data reflect advancements over 32 years and >40,000 transplants, providing insights for evaluating emerging DLBCL therapies.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: